For quantification of cGMP directly obtained from cell lysates, tissue homogenates, plasma, or urine
Features
  • Detect non-acetylated or acetylated cGMP in cell lysates, tissue homogenates, plasma, or urine
  • Measure non-acetylated cGMP levels down to 1 pmol/ml or acetylated cGMP levels down to 0.1 pmol/ml
  • Assay 24 samples in triplicate or 36 samples in duplicate
  • Incubation: 18 hours | Development: 60-90 minutes | Read: Colorimetric at 405-420 nm
  • Contains acetic anhydride
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Product Categories

Product Type

Assay & Reagent Kits
Assay Kits
ELISA

Research Area

Cell Biology
Cell Signaling
cGMP Signaling

Application

ELISA

Cyclic GMP ELISA Kit

Item No. 581021

Kit Booklet (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • cGMP EIA Kit
  • Guanosine 3',5'-cyclic mononucleotide
  • Guanosine 3',5'-cyclic monophosphate
  • Monosodium-GMP
Assay Range
0.23-30 pmol/ml
Sensitivity
80% B/B0: 1 pmol/ml
Cross Reactivity
(Non-Acetylated cGMP) 9%(Non-Acetylated Dibutyryl cGMP) 0.8%(Non-Acetylated AMP) <0.01%(Non-Acetylated ATP) <0.01%(Non-Acetylated cAMP) <0.01%(Non-Acetylated 8-bromo-cGMP) <0.01%(Acetylated cGMP) 100%(Acetylated cAMP) 0.05%(Acetylated adenosine) <0.01%(Acetylated AMP) <0.01%(Acetylated cytidine) <0.01%(Acetylated guanosine) <0.01%(Acetylated uridine) <0.01%(2'3'-cGMP) <0.01%
Origin
Animal/Bovine, Animal/Eel, Animal/Mouse, Animal/Rabbit
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    96 solid wells

    $380

    Add

    96 strip wells

    $380

    Add

    480 solid wells

    $1,518

    Add

    480 strip wells

    $1,518

    Add
    Bioanalysis & Assay Development Services
    Your Vision. Our Expertise.
    • Bioanalysis and compound screening using Cayman or qualified commercial assay kits
    • Development and qualification of fit-for-purpose assays in a variety of formats and platforms
    • Experienced scientists dedicated to developing the best strategy for your project
    LEARN MORE
    Product Description

    The Cayman Chemical cGMP Assay is a competitive ELISA that can be used for quantification of cGMP directly obtained from cell lysates, tissue homogenates, plasma, or urine. The assay has a range from 0.23-30 pmol/ml and a sensitivity (80% B/B0) of approximately 1 pmol/ml. Since the antibody used in this assay was prepared against a cGMP-carrier protein conjugate, antibody binding is increased if an acetyl group is present on the 2' hydroxyl group of the cGMP. The optional acetylation procedure for both samples and standards increases the sensitivity of the assay approximately 10 fold. A protocol for acetylating both the standards and samples prior to performing the assay is provided. Basal levels of cGMP in cell lysates can often be measured without acetylation, but results will depend on the type and number of cells being utilized. Platelets produce approximately 1.5-2.5 pmol cGMP/109 platelets under basal conditions.1,2,3 Cells such as NG108-15 cells and monocytes produce considerably more cGMP than platelets (approximately 0.1-1 pmol/106 cells).4,5

    Needed but not supplied: Please download the kit booklet to verify if UltraPure Water (Milli-Q or equivalent) or any other components are needed for this assay.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Chen, L., Salafranca, M.N., and Mehta, J.L. Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. Am. J. Physiol. 42, H1854-H1859 (1997).

    2. Miller, O.V., and Gorman, R.R. Modulation of platelet cyclic nucleotide content by PGE1 and the prostaglandin endoperoxide PGG2. J. Cyclic Nucleotide Res. 2, 79-87 (1976).

    3. Wu, C.C., Ko, F.N., Kuo, S.C., et al. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 116(3), 1973-1978 (1995).

    4. Arima, T., Ohshima, Y., Mizuno, T., et al. Cyclic GMP elevation by 5-hydroxytryptamine is due to nitric oxide derived from endogenous nitrosothiol in NG108-15 cells. Biochem. Biophys. Res. Commun. 227, 473-478 (1996).

    5. Kolb, J.P., Paul-Eugene, N., Damais, C., et al. Interleukin-4 stimulates cGMP production by IFN-γ-activated human monocytes. Involvement of the nitric oxide synthase pathway. The Journal of Biological Chemisty 269, 9811-9816 (1994).

    Product Citations

    Burnat, G., Santocki, M., Kalinowski, L., et al. The impact of muscarinic and mGlu receptors modulators on MK-801-induced impairments in NO-dependent processes both in vitro and in vivo. Pharmacol. Rep. 77(5), 1309-1322 (2025).

    Datunashvili, M., Chaudhary, R., Zobeiri, M., et al. Modulation of hyperpolarization-activated inward current and thalamic activity modes by difference cyclic nucleotides. Front. Cell. Neurosci. 12, 369 (2018).

    Flores-Costa, R., Alcaraz-Quiles, J., Titos, E., et al. The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. Br. J. Pharmac. 175(6), 953-967 (2018).

    Matouk, A.I., Taye, A., El-Moselhy, M.A., et al. The effect of chronic activation of the novel endocannabinoid receptor GPR18 on myocardial function and blood pressure in conscious rats. J. Cardiovasc. Pharmacol. 69(1), 23-33 (2017).

    Baldissera, L., Jr., Squebola-Cola, D.M., Calixto, M.C., et al. The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxis. Pulm. Pharmacol. Ther. 41, 86-95 (2016).

    Syed, A.A., Lahiri, S., Mohan, D., et al. Cardioprotective effect of Ulmus wallichiana planchon in β-adrenergic agonist induced cardiac hypertrophy. Front. Pharmacol. 7:510, (2016).

    Impagnatiello, F., Toris, C.B., Batugo, M., et al. Intraocular pressure-lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical models. Invest. Ophthalmol. Vis. Sci. 56(11), 6558-6564 (2015).

    Claybaugh, T., Decker, S.J., McCall, K., et al. L-Arginine supplementation in type II diabetic rats preserves renal function and improves insulin sensitivity by altering the nitric oxide pathway. Int. J. Endocrinol. 171546 (2014).

    Leiria, L.O., Silva, F.H., Davel, A.P., et al. The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice. J. Urol. 191(2), 539-547 (2014).

    Krauss, A.H.P., Impagnatiello, F., Toris, C.B., et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp. Eye Res. 93(3), 250-255 (2011).

    Kang, K.K., Ahn, G.J., Sohn, Y.S., et al. DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension. J. Int. Med. Res. 31(6), 517-528 (2003).

    Li, Z., LaPenna, K.B., Gehred, N.D., et al. Dysregulated protein s-nitrosylation promotes nitrosative stress and disease progression in heart failure with preserved ejection fraction. Circ. Res. 137(9), 1185-1206 (2025).